Pinealon
EDR peptide, Glu-Asp-Arg, EDR tripeptide, Pinealon-6
The Ground Truth Score
four plain questions, never one numberRussian lab data is real but comes from one research group, and no controlled human trial exists outside Eastern Europe. The sleep effects Huberman reports are anecdote, not evidence.
Bottom line
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, with a plausible neuroprotective mechanism supported by cell-culture and rodent studies, five small, uncontrolled Russian human reports (none measuring sleep), and no independent replication. That puts it squarely in the 'interesting but unverified' tier.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
Research-onlyNo legal consumer routeSold labeled 'for research use only, not for human consumption.' There is no approved product, no compounding path, and no one verifying identity, purity, or dose. That label is not a formality, it is the entire legal basis on which it can be sold to you at all.
No FDA-approved product and no 503A compounding route; not nominated or listed in any FDA category as of the May 14 2026 list. Sold labeled for research use only, which is the legal basis on which it can be sold at all.
Legal status as of 2026-10-12. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓100-300 mcg SubQ once daily, evening, in 10-20 day cycles (community reported); no established human protocol
Reported, not prescribed. Verify your vial and your math.
The gist
- People use it for REM sleep and brain aging, mostly off the back of Huberman's n=1 report where he co-administered glycine, so attribution is impossible.
- The preclinical science is real but comes entirely from one Russian lab, and one of the small PubMed-indexed human reports found inhibition of blood stem cell production, which nobody in the community talks about.
- Oral bioavailability is expected to be near zero for a tripeptide; the Russian clinical protocol used oral dosing anyway, which means the route-of-administration question alone is still completely open.
First documented human use
No controlled human trial has been completed in the Western peer-reviewed literature. PubMed indexes five small, uncontrolled Russian reports that include Pinealon (2012 to 2016), none measuring sleep. The Khavinson group reports, in a 2020 review, that oral Pinealon alongside standard therapy helped memory and headaches in 72 patients with brain-injury aftereffects. That figure traces to a 2013 review article, not to a trial report, and has no controls, dose or duration that we could verify. None of it has been independently replicated.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Supports pineal gland function and endogenous melatonin production
- Protects neurons against oxidative stress and age-related decline
- May improve memory and cognitive performance after brain injury
- Promotes restorative REM sleep when used intermittently
- May slow biological markers of brain aging via epigenetic regulation
The data behind each bullet
What actually backs it
Pinealon reduces reactive oxygen species in neuronal cell cultures
In vitro study in cerebellar granule cells, neutrophils, and PC12 cells showed dose-dependent ROS suppression and delayed ERK1/2 activation under oxidative stress conditions. Cell-culture finding, not a human trial. Single research group.
Khavinson et al. 2011, Rejuvenation Research, PMID 21978084 ↗Pinealon restores neuronal dendritic spine density in Alzheimer's disease cell models
Mouse hippocampal neuron cultures exposed to amyloid-induced synaptotoxicity showed 71% increase in mushroom spine number at 200 ng/ml EDR. In vitro only. Authors explicitly recommended further experimental study before clinical application.
Kraskovskaya et al. 2017, Bull Exp Biol Med, PMID 28853087 ↗Pinealon improves offspring cognition when given to pregnant rats exposed to high homocysteine
Rat model: pregnant animals on high-methionine diet received EDR; offspring showed improved spatial orientation, learning, and reduced cerebellar neuron ROS. Rodent model of prenatal metabolic stress. Not translatable to healthy adult humans.
Arutjunyan et al. 2012, Int J Clin Exp Med, PMID 22567179 ↗Pinealon improves memory in patients recovering from traumatic brain injury
The Khavinson group's 2020 review states that oral Pinealon alongside standard therapy helped memory and headaches in 72 patients with brain-injury aftereffects. That figure traces to a 2013 review article (PMID 24738258), not to a trial report. No placebo arm, controls, dose or duration could be verified, so this claim cannot be independently checked from public sources.
Khavinson et al., Molecules 2020, EDR peptide review (cites the 72-patient report) ↗No human study of Pinealon measured sleep.
All five indexed human abstracts (2012 to 2016) report biological-age, adaptation, psychoemotional or work-ability measures; none reports sleep.
Meshchaninov et al., Adv Gerontol 2015 (and four others) ↗Pinealon interacts with DNA to epigenetically regulate neuroprotective gene expression
Molecular docking and ion-interaction models show Glu-Asp-Arg partly penetrates the major groove of DNA, potentially affecting guanine N7/O6 base atoms. HeLa cell fluorescence confirms cellular penetration. This is a proposed mechanism only, not proven to cause specific gene expression changes in human neurons in vivo.
Silanteva et al. 2019, role of ions in Glu-Asp-Arg-DNA interaction (J Phys Chem B, PMID 30762356) ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it, a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
The only honest tracker is REM sleep on a wearable (Oura/WHOOP/Eight Sleep) run as a strict n-of-1, it measures the one claimed endpoint at home, but there is zero human validation and the evidence is D-grade.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
Pinealon (Glu-Asp-Arg / EDR) is a short-peptide bioregulator proposed to act as an intranuclear epigenetic regulator of neuronal gene expression in CNS tissue. Its claimed actions are local and transcriptional, so it produces no systemic analyte that a routine blood panel measures.
Read this before you spend on labs
Routine bloodwork cannot confirm pinealon is working. Its claimed effects are neurocognitive and subjective (memory, headache relief, mood, sleep), and the human evidence is limited to Russian TBI/cerebrasthenia trials that measured symptom and cognitive scales, not blood markers. No LabCorp/Quest analyte moves in a direction that reflects its biological action. Despite the "pineal" name and melatonin-support marketing, there is no controlled human data showing it raises measurable serum or urinary melatonin/6-sulfatoxymelatonin as an efficacy readout, so those are not usable proxies. The single blood finding in the literature is an unreplicated adverse signal (decreased CD34+ hematopoietic progenitor cells); that is a safety flag requiring specialized flow cytometry, not an efficacy marker, and must not be read as proof of benefit. Any objective anchor lives in validated cognitive/symptom testing, not in blood.
Other ways to track it
Oura Ring, WHOOP, or Eight Sleep, nightly REM minutes as the only claimed endpoint; nocturnal HRV and resting HR tracked ONLY as confound/context (recovery load, illness, alcohol), not as pinealon efficacy signals
A working result would show a sustained rise in nightly REM minutes over weeks versus your own baseline. Judge rolling weekly averages, never single nights, consumer wearables stage REM only moderately well against lab PSG, so night-to-night swings are noise. Do NOT read HRV or resting-HR shifts as the peptide working: those are general recovery metrics with no pinealon-specific claim, useful only to catch confounds (poor nights, illness, alcohol). Ignore any 'deep-sleep' expectation, even the single public anecdote was REM-only, so deep-sleep/SWS is not a claimed endpoint and wearable SWS staging is weaker still. Run it as a clean n-of-1: no glycine, magnesium, or other sleep aids started at the same time (the lone 'REM doubling' anecdote was confounded by concurrent glycine).
Pinealon's headline consumer claim is restorative/REM sleep, and REM is the one claimed endpoint a home wearable estimates, so this is a legitimate n-of-1 outcome check, not a mechanistic proxy. But there is NO human sleep trial: evidence is D-grade (in-vitro/rodent work from a single Russian lineage, a TBI/cognition trial that never measured sleep, and one uncontrolled anecdote). The wearable can track whether the claimed endpoint moves in you, but cannot establish that pinealon caused it.
Bottom line
Pinealon has no blood proxy and no validated objective biomarker, its mechanism is intranuclear/epigenetic with nothing measurable on a systemic panel, and its human evidence is D-grade (cell and rodent studies plus five small uncontrolled Russian human reports, none measuring sleep, and one uncontrolled REM anecdote). A sleep wearable can track the single thing it claims to change, nightly REM, as a strict n-of-1, but any change is easily confounded by glycine, sleep habits, or seasonality, and consumer REM staging is imprecise. HRV and resting HR are context only, not efficacy signals; deep-sleep, cognition, neuroprotection, and 'melatonin support' claims have no accessible objective readout at all. Treat a positive multi-week n-of-1 REM trend as suggestive, never proof.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data, bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
ASSUMED (theoretical, not proven in vivo in humans). Pinealon (Glu-Asp-Arg) is proposed to act as a short-peptide epigenetic regulator: the tripeptide penetrates cell nuclei (confirmed in HeLa cell fluorescence studies) and is modeled to interact with guanine base atoms in DNA promoter regions. This is proposed to upregulate genes involved in neuroprotection, antioxidant defense (via MAPK/ERK pathway modulation), and apoptosis suppression. In pineal gland tissue specifically, it is theorized to activate CREB transcription factor to upregulate melatonin synthesis genes (AANAT). All of this is mechanistically plausible and partially supported by cell-culture data, but has not been demonstrated in human tissue in vivo.
Dosing & handling
What users and clinicians report
Community-reported protocols vary significantly. Injectable: 100-300 mcg subcutaneous, daily or several nights per week, evening dosing. Oral: the one human dose we could source is 100 mcg twice daily for 2 weeks (Nazimko 2012). Huberman describes intermittent pulsed use (not nightly). Course lengths of 20-30 days with 3-6 month gaps are most commonly cited.
These are community-reported protocols, not prescribed doses. Oral bioavailability for a tripeptide is expected to be very low (gastric peptidase degradation). No human pharmacokinetic study exists to confirm what dose actually reaches the CNS. The biggest dosing risk is the complete absence of dose-safety data in healthy adults for any route. The one oral human dose (100 mcg twice daily for 2 weeks) comes from a small uncontrolled study in locomotive crews, not a healthy-adult optimization protocol.
Timing & food
Community consensus favors evening administration (1-2 hours before sleep) to align with the proposed melatonin and pineal gland mechanism. Some protocols use morning dosing for the cognitive claims. The oral Russian study used twice-daily dosing without timing specificity in available summaries. No pharmacokinetic basis for timing guidance exists.
Half-life
Unknown. No human or animal pharmacokinetic study exists for Pinealon. Theoretical estimates based on short tripeptide structure suggest plasma half-life of minutes to 1-2 hours. Subcutaneous absorption timeline is uncharacterized. Oral bioavailability is expected to be very low (gastric acid and peptidase degradation of tripeptides) but has not been measured.
Reconstitution sensitivity
Standard peptide reconstitution applies: bacteriostatic water, store refrigerated at 2-8C after reconstitution. Stable approximately 30 days reconstituted. Protect from light. Avoid repeated freeze-thaw. No Pinealon-specific reconstitution sensitivity data exists.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Growing but still thin. Huberman's public endorsement in 2023-2024 seeded a wave of community reports, but the total user base is small compared to compounds like BPC-157 or TB-500. Most English-language discussion is recent and Huberman-catalyzed.
Consistency
Reports on sleep and vivid dreams are reasonably consistent. Cognitive effects are inconsistent and harder to attribute. The sleep signal is the strongest community thread.
Source credibility
Low-to-moderate. Many community reports involve co-administration with glycine (which has its own strong sleep data), Epitalon, or TRT. Independent single-compound Pinealon reports are rare. Huberman's self-report is the highest-credibility anecdote but it is still an uncontrolled n=1.
- Anecdote: the most consistent report is unusually vivid or intense dreams, sometimes described as cinematic. This appears in both the Russian clinical literature (as a minor side effect) and Western community reports.
- Anecdote: users report improved sleep depth and subjective morning alertness within 1-2 weeks of starting. Almost universally co-administered with glycine, so attribution is unclear.
- Anecdote: some users describe noticeable improvements in focus and word recall during course periods, most often in the 40+ demographic. These reports are impressionistic and not tracked against any baseline.
- Anecdote: Huberman said on his podcast that a dose at a mid-night waking raised his late-night REM from about 1.5 to about 3 hours, with pulsed use of about three times a month at most. He later stopped. This is the single highest-visibility self-report and has driven much of the Western interest.
Placebo risk, High
Sleep quality and cognitive function are highly subjective and highly susceptible to expectation effects, especially when used by biohackers who are actively tracking, optimizing, and paying attention to their metrics. Vivid dreams and any perceptible sleep sensation provide a concrete 'signal' that reinforces belief in the compound working. No objective biomarker (like GH secretion for GHRP-2) exists for the primary claimed benefits.
Risk panel
What could go wrong
Adverse events
Minimal adverse events reported in the Russian clinical and preclinical literature. Injection-site reactions (redness, mild swelling) are the most commonly listed. Some users report very vivid or intense dreams, transient mild headache, and minor fatigue. Small blood sugar drops noted in a small number of anecdotal reports. No serious adverse events documented in available published material. One of five small PubMed-indexed human reports (PMID 26390612, 32 patients) found significant inhibition of hemopoiesis as measured by decreased CD34+ hematopoietic progenitor cells. That study's authors explicitly called for additional safety studies before broader use.
Theoretical concerns
Pinealon targets the central nervous system and is claimed to influence epigenetic gene regulation. Long-term consequences of exogenous epigenetic modulation in healthy adults are completely unstudied. Any peptide with CNS activity in a poorly characterized population carries unknown risk. Melatonin-pathway modulation could theoretically disrupt circadian regulation if used chronically and incorrectly timed. The hemopoiesis inhibition signal from one small PubMed-indexed human report adds an unresolved safety question that has not been followed up in any published study.
Contraindications
Pregnancy and lactation (by convention, not proven risk). Active seizure disorders or a history of neurological conditions warrant caution given CNS targeting. Under 18. Allergy to any component. Given the hemopoiesis inhibition signal found in PMID 26390612, individuals with blood disorders or on chemotherapy or immunosuppressive agents should exercise additional caution.
Honest unknowns
No pharmacokinetic data (half-life, bioavailability, distribution, clearance) exists from formal human or animal studies. Oral bioavailability is theoretically very low for a tripeptide but has not been measured. Long-term effect on endogenous pineal or melatonin regulation is unknown. Interactions with TRT, GLP-1 agonists, melatonin supplements, or other peptides are unstudied. The clinical significance of the hemopoiesis inhibition signal from the 2015 human study is unknown, as no follow-up study has been published.
Confound watch
The biggest confound in community reports is co-administration with glycine (3-5g oral), which independently improves sleep quality and REM in controlled trials and is commonly paired with Pinealon in clinician protocols (Dr. Craig Koniver recommends 3 to 5 g), so any sleep effect is hard to attribute. Users also frequently stack Pinealon with Epitalon (another Khavinson pineal bioregulator), making cross-compound attribution impossible. TRT independently improves sleep architecture and cognitive function. The wellness community stacks these together and attributes outcomes to Pinealon by default.
History
Discovery → first use → status
- 1970s-1980sVladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology begin developing short peptide bioregulators derived from organ extracts, originally for Soviet military and cosmonaut health programs. Cortexin (polypeptide brain extract) precedes the synthetic tripeptide era.
- 2000s-2010sThe EDR tripeptide (Glu-Asp-Arg) is isolated and synthesized as a defined compound from the broader Cortexin bioregulator research. Khavinson group publishes foundational in vitro and rodent neuroprotection studies establishing the 'pinealon' name and proposed mechanism.
- 2011-2017Core preclinical evidence published: ROS suppression in cerebellar cells (2011, PMID 21978084), prenatal rat neuroprotection (2012, PMID 22567179), dendritic spine restoration in Alzheimer's cell model (2017, PMID 28853087). All Khavinson-affiliated. No independent replication.
- 2015One of five small PubMed-indexed human reports that include Pinealon as one of the tested compounds is published in Advances in Gerontology (PMID 26390612). The 32-patient uncontrolled observational study in elderly patients with polymorbidity and organic brain syndrome found that Pinealon had significant anabolic effects and slowed aging by biological age indicators, but also found significant inhibition of hemopoiesis (decreased CD34+ hematopoietic progenitor cells in blood). The authors called for additional safety studies. This is not a healthy-adult optimization study. Vesugen, not Pinealon, showed the stronger geroprophylactic effect in this study.
- 2023-2026Andrew Huberman says on his podcast that he tried Pinealon a few times, about three times a month at most, and that a dose at a mid-night waking raised his late-night REM from about 1.5 to about 3 hours. He later stopped, saying he did not know enough about it. No change to the underlying evidence grade.
Verification
The COA standard, applied
Cross-checked against the cited sources below. The grade reflects the absence of formal human safety and efficacy data. The TBI human study has no publicly accessible primary source and is treated as unverified; a 2020 Molecules review is cited for it. PMID 26390612, one of five small PubMed-indexed human reports including Pinealon, reported a hemopoiesis-inhibition signal, which is reflected in the risk section.
The full verification standard →Sources
Where this comes from
- Khavinson et al. 2011 - Pinealon increases cell viability by suppression of free radical levels (PMID 21978084) ↗· Core in vitro neuroprotection paper. Cerebellar granule cells, neutrophils, PC12 cells. Dose-dependent ROS suppression and ERK modulation. Real study but preclinical only.
- Kraskovskaya et al. 2017 - Tripeptides restore neuronal spines in Alzheimer's disease model (PMID 28853087) ↗· In vitro mouse hippocampal neuron study. EDR (Pinealon) at 200 ng/ml restored mushroom spine count by 71% under amyloid synaptotoxicity. Authors called for further study, not clinical use.
- Arutjunyan et al. 2012 - Pinealon protects rat offspring from prenatal hyperhomocysteinemia (PMID 22567179) ↗· Rodent model, not human. Establishes the neuroprotective and cognitive claims at the animal level. The most cited animal study.
- Silanteva et al. 2019 - Role of mono- and divalent ions in peptide Glu-Asp-Arg-DNA interaction, J Phys Chem B (PMID 30762356) ↗· Molecular mechanism paper. Models how Glu-Asp-Arg interacts with DNA base atoms. Underlies the epigenetic regulatory claim but is computational, not a human gene expression study.
- Meshchaninov et al. 2015 - Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome (PMID 26390612, Advances in Gerontology) ↗· One of five small PubMed-indexed human reports that include Pinealon, and the one with the most detail. 32 patients (18 men, 12 women, ages 41-83), uncontrolled observational design, not a healthy-adult trial. Found anabolic effects and slowed biological aging indicators but also found significant inhibition of hemopoiesis (decreased CD34+ progenitor cells). Authors called for additional safety studies. Vesugen showed stronger effect than Pinealon in this study.
- Nazimko et al. 2012 - Pinealon capsules in locomotive crews, 100 mcg twice daily for 2 weeks (PMID 22708445, Advances in Gerontology) ↗· The only human source with a stated dose. Oral capsule, no controls described; better biological-age indicators reported. Also see Bashkireva 2012 (PMID 23734521) and Myakotnykh 2016 (PMID 28539017).
- Khavinson et al. 2020 - EDR peptide review, Molecules (PMC7795577) ↗· Source of the 72-patient brain-injury statement. It cites a 2013 review (PMID 24738258) whose abstract gives no patient numbers.
- Khavinson et al. 2021 - tripeptides in a mouse Alzheimer's model, Pharmaceuticals (PMID 34071923) ↗· Animal study from the same group.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.